Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Urologic Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Letrozole 22Radiotherapy 21Doxorubicin 21Megestrol Acetate 20lenvatinib 19olaparib 18Taxes 17Docetaxel 17Nivolumab 16Specimen Handling 15Metformin 15dostarlimab 14Magnetic Resonance Spectroscopy 14Gemcitabine 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11Biopsy 11temsirolimus 10abemaciclib 10atezolizumab 9Radiation 9Early Intervention, Educational 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Endometrial Neoplasms × VMBP protocol × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡